my 2 cents

Just like to add my 2 cents here.

I have been following this stock somewhat for a while now.

Briefly the application is one which is much sort after in medicine and has been for some time.
The more severe head injuries are horrendous medical problems often requiring extended ICU stays with various interventions to try to improve outcomes. Unfortunately it is not easy to predict how people will do following a head injury and all stops are pulled out, often with very poor outcomes.
A drug with ANY improvement in outcomes will be very appealing to clinicians looking after these people. The market uptake in these severe cases I think would be very rapid. The less severe cases will take considerable more time to adopt but obviously the market is much bigger.

This has run sooner than I expected, I think somewhat due to ANP putting the spotlight on other biotech.
(I think NEU has a substantially better potential product here and are further down the trails tract.)

Very promising stock